Cryptococcal meningitis (CM) is a leading cause of meningitis in many low-and middle-income countries (LMICs), where it accounts for 15%-20% of all human immunodeficiency virus (HIV)-related deaths [1] . Despite the expansion of antiretroviral therapy (ART) programs, rates of CM remain high, because many HIV-infected persons begin ART late and face difficulties maintaining effective treatment [2] . Moreover, sustainable access to the current reference induction treatment, flucytosine (5-FC) and amphotericin B (AmB), is a major challenge in these settings [3] . Fluconazole monotherapy is the only alternative but is associated with higher short-term mortality, even at high dosages [4] . Consequently, CM mortality remain high in LMICs, ranging from 22% to 96% [5, 6] at 10-12 weeks. In contrast, it has been estimated to range from 9% to 15% in Western Europe and North America [7, 8] .
In addition, a growing number of CM-associated deaths occur in non-HIV patients in high-income countries (HICs) [9] . CM caused by Cryptococcus neoformans, is increasingly observed among patients with non-HIV immunosuppression [9] . In parallel, Cryptococcus gattii CM, endemic in Australia, appeared recently as an outbreak in North America, mainly among patients without apparent immunosuppression (up to 72% of cases). Mortality outcomes for non-HIV-associated CM (non-HIV-CM) seem to be no better than those for HIV-associated CM (HIV-CM) in similar settings [9] .
Beyond mortality, CM survivors may experience longterm (≥3 months after CM diagnosis) neurological and sensorial impairment, resulting in disability and poor quality of life [7, 10] .
However, data on long-term outcomes in CM remain scarce [11, 12] . Indeed, while short-term mortality for HIV-CM has been well reviewed [8, 9, 13, 14] , literature reviews including longer-term overall cryptococcosis mortality are limited [9, 14] , and none have reported on long-term CM-related neurosensorial impairment and disability.
To address this gap, we exhaustively reviewed published data on the long-term mortality, impairment, and disability associated with CM caused by C. neoformans or C. gattii in either immunodeficient or immunocompetent adults. We addressed the following questions: What are the proportions/rates and predictive factors for death occurring ≥3 months after CM diagnosis or treatment induction? What are the nature, frequency, and predictive factors for CM sequelae/impairment, disability and decreased quality of life ≥3 months after CM treatment induction? Finally, are there differences in ≥3-month prognosis between HIV-infected and non-HIV infected patients?
METHODS
This systematic review was conducted in line with the PRISMA Statement [15] . Long (Figure 1 ). The search combined 2 groups of words, including synonyms and MeSH terms for "cryptococcal meningitis" (group 1) and "outcome and risk factors" (group 2) (see Supplementary Table S1 ).
All types of study design were considered for eligibility. Studies were included if they fulfilled the following criteria: (1) reporting the mortality rate/proportion and/or the proportion of sequelae/impairments/disability occurring ≥3 months after CM diagnosis or after induction treatment, (2) participants ≥18 years-old, and (3) documented first episode of CM diagnosis based on positive india ink and/or positive cryptococcal antigen (CrAg) results and/or positive culture (C. neoformans or C. gattii), in cerebrospinal fluid (CSF). Both immunodeficient and apparently immunocompetent patients were considered. Studies on cryptococcomas without CM and studies where CM data could not be individualized from other causes of meningitis were excluded. Additional studies were manually searched for from reference lists of all identified articles.
Quality Assessment
The quality of the selected studies was assessed at outcome level [15] using the Critical Appraisal Skills Programme (CASP) tools [16] . Three domains were assessed: (1) validity: appropriate design, appropriate sampling methods, risk of bias and confounding; (2) importance: effect size, power, precision of study; and (3) comparability/generalizability. Studies that fulfilled >70% of criteria were considered of good quality and those that fulfilled <50% of CASP criteria were excluded for providing weak evidence.
Data Extraction and Synthesis
For each study included, the following data were extracted: (1) study characteristics (setting, design, sample size, statistical method used, potential bias and confounding), (2) participant characteristics (eligibility criteria; age; sex; immunological, mental and ART status at diagnosis; timing of ART initiation), (3) Cryptococcus species, (4) outcome (mortality proportion/rate, impairments/disability proportion, and quality of life) stratified by outcome timing (6, 12 , and >12 months after diagnosis), and (5) predictive factors (age, immunological status, viral load, CSF characteristics, clinical presentation, mental and ART status at diagnosis, antifungal and ART treatment received, adjunctive therapy, setting, Cryptococcus species, occurrence of immune reconstitution inflammatory syndrome (IRIS), opportunistic coinfections/ affections).
Quality assessment of included studies showed high heterogeneity; we therefore decided to undertake a qualitative synthesis rather than a meta-analysis, which included describing the studies and their results and limitations without pooling estimates. Further synthesis of the results was done with predefined subgroups by patients' immunological status (HIV infected or non-HIV infected). 
RESULTS

Study Characteristics
Of the 6035 records identified during the study period, 177 were selected for full-text review, and 25 articles (24 studies: 4 randomized controlled trials [RCTs], 11 prospective cohort studies, and 9 retrospective cohort studies) were eventually retained ( Figure 1 ) [11, 12 17-39] . Only 1 of the studies [11] was included despite not fulfilling the inclusion criteria, because it provided key results on disability. Twenty-one studies provided information on mortality outcomes, 6 on impairments, 2 on disability, and none on quality of life. All continents were represented, with 15 studies from LMICs and 9 from HICs. Only 6 studies (25%) fulfilled ≥70% of quality criteria: 2 RCT and 4 cohort studies (Table 1) .
Long-term Mortality and Predictive Factors
In HIV-CM, 17 articles provided information on CM mortality outcome (5 from HICs and 12 from LMICs), and 10 examined risk factors (Table 2 ). Five articles (28%) fulfilled ≥70% of quality criteria. Available data suggest that the high mortality rate in the first 10 weeks of treatment continues to rise slowly, leveling off after 6 months of treatment [11] [12] [13] [14] [15] [16] [17] . However, evidence was weak, with few studies and difference in CM management across studies. Two studies using survival analysis showed that with the use of both AmB-based combination therapy and appropriately timed ART, the survival curve strongly flattens after 3 months [20, 21] . There was important variation in the 1-year mortality according to both setting and period: in HICs, the mortality was about 50% in the pre-ART period [22] and 20% in the late ART period [22] [23] [24] , whereas it ranged from 39.5% to 78% in LMICs [17] [18] [19] [20] [21] [25] [26] [27] . The 1-year mortality also varied according to the induction treatment received, with fluconazole performing worse than AmB monotherapies, which, in turn, performed worse than AmB-based combined therapy ( Figure 2 ). Nevertheless, even with the latter, the 1-year mortality was about 40% [19, 20] in LMICs and about 20% [22] [23] [24] in HICs. Other protective factors included the use of ART, as shown in France [22] and Denmark [24] , and, in ART-naive patients, delaying the introduction of ART to 5-10 weeks after induction therapy compared with an introduction between 3 days and 2 weeks [20, 28] . In LMICs, the 1-year mortality observed in patients with aggressive management of intracranial pressure was lower than in those without such management (40% [19, 20] vs 59% [18] , respectively).
In HIV-CM, the main independent risk factors for long-term mortality were altered neurological status [11, 25] , low CD4 cell count [23] , high CSF fungal/CrAg burden [11, 25] , and older age [24] at diagnosis (Table 3) . Finally, the association between IRIS and higher long-term mortality is still unclear [20, 29, 30] with only 1 study of the 3 that addressed this question showing a significant association [30] . This may result from the small study sizes or from the IRIS definition adopted, which may miss early IRIS, leading to an ascertainment bias, as suggested by Boulware et al [20] .
In non-HIV-CM, evidence on long-term mortality is weaker; only 6 articles were identified (including none from LMICs), and none fulfilled ≥70% of quality criteria (Table 4) . One-year mortality ranged from 13.7%, in an Australian cohort infected by C. gattii with underlying conditions in only 28% of patients [12, 31] to 42.3%, in a Taiwanese study with underlying conditions in all patients [23] . Non-HIV-CM mortality may continue to rise after 3 months, as suggested by data from Liao et al [23] .
The main independent risk factors for 1-year mortality in non-HIV-infected patients were delayed diagnosis [32] , age >60 years [32] , altered initial neurological status [23, 32] , high CSF CrAg level [23] and non-AmB-based versus AmB-based induction therapy [32, 39] (Table 5 ). In patients with C. gattii CM, only high CSF CrAg levels were found to be independently associated with 1-year mortality [12] .
Long-term Neurosensorial Impairments and Disability and Their Predictive Factors
Seven studies provided evidence on neurosensorial impairment and disability (3 for HIV-CM and 4 for non-HIV-CM), and only 1 fulfilled ≥70% of quality criteria [33] (Supplementary  Table S2 ).
In HIV-CM, up to 69.2% of survivors from a Taiwanese cohort had neurosensorial sequelae 1 year after diagnosis [23] mainly residual headache (38%), motor deficit (15%), and vertigo (15%). In a Ugandan study, cognitive function remained impaired in 41% of survivors, although the contribution of HIV encephalitis should also be questioned [33] .
Only 2 studies assessed long-term disability related to HIV-CM [11, 33] , and none used the WHO International Classification of Functioning definition [10] . In the clinical trial reported by Day et al [11] , 40% of the survivors reported having some form of "disability" at 6 months, and in the cohort study reported by Carlson et al [33] , 11% of survivors declared themselves unable to work at 1 year.
Few predictive factors of long-term impairments and disability were found. Carlson et al [33] demonstrated that the risk of 12-month impaired cognition was increased in HIV-CM patients with lower CD4 cell counts at induction. Paradoxically, persons with sterile CSF cultures after 14 days of AmB therapy had worse neurocognitive outcomes than those who were still culture positive. At 6 months, Day et al demonstrated that patients treated with AmB plus 5-FC were half as likely to report a disability as patients treated with AmB monotherapy [11] .
In non-HIV CM, findings were heterogeneous. In 2 cohorts of patients infected with C. gattii without underlying conditions, the rates of neurosensorial sequelae among 1-year survivors were between 19% and 24% [12, 34] . This proportion reached 73.3% in a cohort of patients with underlying conditions (Cryptococcus species not known) [23] . The main impairments were vertigo (13%-24%), visual loss (13%-23%), hearing impairment (6%-17%), and motor deficit (3%-16%). Sylvian fissure enhancement seen with magnetic resonance imaging and CSF CrAg titers >1/256 at induction were, respectively, independently associated with hearing loss in any non-HIV-CM [35] , and neurological sequelae in C. gattii cohorts [12] .
Comparison Between HIV-CM and Non-HIV-CM
The 3 studies comparing long-term mortality between HIV-CM and non-HIV-CM [23, 36, 37] gave contradictory results.
Nevertheless, valid comparisons are prevented by the studies' heterogeneity in terms of proportions of ART-naive patients for HIV-CM and proportions of patients with underlying conditions for non-HIV-CM.
DISCUSSION
Long-term Impact of CM on Mortality, Impairment, and Disability
To our knowledge, this is the first literature review focusing on long-term outcomes of CM, including death, neurosensorial impairment, and disability. Our review shows that the mortality Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; d90, day 90 after diagnosis or induction treatment; d120, day 120 after diagnosis or induction treatment; HIC, high-income country; HIV-CM, human immunodeficiency virus-associated cryptococcal meningitis; LMIC, low-or middle-income country; PC, prospective cohort; PD, percentage of deaths; RC, retrospective cohort; RCT, randomized controlled trial; SA, survival analysis. a Mortality expressed as PD at the time point (those lost to follow-up excluded when known) or as SA (probability of death at a time point, those lost to follow-up censored). Parenthetical numbers represent No./total when mortality is expressed as PD and provided, or 95% confidence intervals when mortality is expressed as SA and provided. can reach 78% in HIV-CM [27] and 42% in non-HIV-CM [23] at 1 year. In addition, regardless of the species studied (C. neoformans, C. gattii), we found supportive evidence for an important long-term burden of CM on impairments and disability, with proportions reaching up to 70% in both HIV-infected and non-HIV-infected survivors [23] . These findings demonstrate that the long-term prognosis of CM in adults may be at least as poor as that associated with other causes of encephalitis in France (33% with impairment at 3 years) [40] or with tuberculosis meningitis (mortality, 20%-60%; impairment among survivors, 20%-50%) [41, 42] .
Prevention of Risk Factors for Long-term Adverse CM Outcomes
Evidence regarding risk factors for long-term outcomes was limited, showing an important gap in knowledge. Each risk factor for long-term outcomes identified was found to be predictive in only 1-3 studies. Some studies did not adjust for confounders (ART [22] and IRIS [20, 29] in HIV-CM, underlying conditions [12, 32] and high CSF antigen titers [35] in non-HIV-CM). Some important potential predictive factors have not been studied (eg, Cryptococcus species, phenotypes and genotypes, intracranial pressure management) and discordant results regarding the effect of IRIS in HIV-CM or underlying conditions in non-HIV-CM were reported. Moreover, definitions of some risk factors varied between studies (neurological abnormalities, fungal burden assessment tools and threshold, underlying disease) limiting the potential for comparison. Therefore, future research should systematically assess the long-term impact of all these risk factors using standardized and validated definitions and tools. Nevertheless, some key actions can be identified to reduce long-term mortality and prevent long-term impairment and disability.
In HIV-CM, some of the well-known short-term mortality risk factors (baseline altered neurological status, high fungal burden, or immunosuppression) [21] also seem to be predictive of long-term adverse outcomes. Their identification could orient clinicians in providing closer clinical follow-up. More importantly, our review identified some evidence for a protective effect of AmB-based combined antifungal regimens with long-term mortality and combined AmB + 5-FC therapy with long-term disability. It has to be noted that only 1 [33] of the 7 cohorts assessing impairments and disability in this review provided AmB-based combined therapy to all patients. Moreover, though ART does not seem to influence shortterm HIV-CM mortality [43] , it plays a key role in reducing long-term mortality [20, 22, 24, 26, 28, 38] . As in tuberculosis meningitis [44] , if introduced appropriately (after 4-5 weeks), ART might protect against other opportunistic infections [20] . Therefore, to prevent not only short-term but also longer-term adverse outcomes, there is an urgent need to scale up access to and coverage of ART, AmB, and especially 5-FC therapy, usually not available in LMICs [45] . In addition, future research on antifungal therapy, as well as adjuvant therapy (especially IRIS and intracranial pressure management), should assess the effect on long-term outcomes, including disability.
In non-HIV-CM, the limited number and heterogeneity of studies preclude firm conclusions on long-term mortality risk factors. In C. gattii cohorts, our results suggest that underlying conditions and altered mental status at induction might be poor long-term prognostic factors [12, 34] . However, these univariable associations might be confounded by other factors. For instance, experimental studies have shown that a difference in virulence of the C. gattii genotype infecting Australian patients (mainly VGI) [46] compared to that infecting of Canadian patients (mainly VGII A) [47] might be another explanation for the difference in mortality. In general, the identified long-term mortality risk factors for non-HIV-CM advocate for early CM diagnosis in persons aged >60 years with underlying conditions. Nevertheless, management guidelines are based on results from trials involving patients with HIV-CM, which may not apply to those with non-HIV-CM. Further multicentric cohorts/trials, as already conducted for solid organ transplant recipients [48] , should therefore be proposed, to further assess these potential predisposing factors and look for the best therapeutic options.
Poor Attention to Impairment and Disability
Although many studies were initially identified, few had high-quality data on long-term outcomes, and only 7 assessed long-term impairments and disability. Only 3 studies assessed impairments/disability and their predictive factors as a primary outcome, and 5 did not describe the method of outcome measurement [12, 23, 31, 34, 36] . None used the WHO definition of disability [10] or assessed quality of life. Similarly, reviews of long-term outcomes of other meningoencephalitis causes [30] , in which the mortality rate is probably underestimated; the patients were included after antiretroviral therapy initiation at a median of 34 days (interquartile range, 24-41 days) after CM diagnosis, missing all deaths occurring during the first weeks. The studies by Lanoy et al (2011) [22] , Liao et al (2012) [23] , and Mathiesen et al (2012) [24] were omitted because no information was available or extractable for the treatment received by the HIV-infected patients or for the dichotomized periods. In the 2007 study by Bicanic et al [26] , 92% of patients were treated with amphotericin B monotherapy, and 8% of patients were treated with fluconazole monotherapy. 5-FC, flucytosine; AmB, amphotericin B; Fluco, Fluconazole.
identified a paucity of studies and very few data on morbidity and impairment [40, 49] . This is indicative of the low value placed on the collection of long-term meningoencephalitis outcomes, especially data on impairment and disability. Very few studies conducted systematic screening for impairments with validated tools, which may lead to misclassifications and underreporting. Indeed, the 2 studies that systematically assessed patients with validated tools found much higher proportions of impairments than the other studies (impaired cognition in 41% of HIV-CM survivors [33] and hearing impairment in 31% of non-HIV-CM survivors [35] ). Therefore, future CM research should focus not only on short-term medical outcomes but also on longer-term impairments, disability, and quality of life. WHO definitions of disability [10] as well as validated neurocognitive, sensorial, and quality-of-life assessment tools should be used as in studies of other forms of encephalitis [40, 49] . [28] RCT ( Despite the limited amount of evidence, it is alarming to see that at 1 year, 20%-70% of survivors have long-term impairments limiting cognitive, motor, visual, and/or hearing function, for both HIV-CM and non-HIV-CM in both LMICs and HICs. Moreover, while research and guidelines focus mainly on management of the acute phase of CM to prevent death in this phase [50] , little attention is given to long-term follow-up and the identification of, and support for, impairments and disability. Therefore, ensuring access to physical, occupational, sensorial, and cognitive rehabilitation services is as important as enhancing prevention by fluconazole preemptive treatment and access to ART and AmB-based therapy [10] . Although these services are routinely accessible in developed countries, they are limited in LMICs owing to a lack of rehabilitation personnel and high costs [51] . For this reason, the development and adaptation of context-specific rehabilitation models should be one of the global research priorities for CM and central nervous system infections, as already advocated by John et al [51] .
Limitations
In addition to the limitations related to the quality and heterogeneity of included studies, our review has some external limitations. Our inclusion and exclusion criteria might have restricted the panel of literature found. Eleven studies have been excluded because they included patients aged <18 years (Supplementary  Table S3 ). Moreover, the chosen threshold of quality is arbitrary, because the CASP group has yet to propose a validated scoring system. This has led to exclusion of an additional 11 articles to decrease the risk of inaccurate conclusions (Supplementary  Table S3 ). Nevertheless, each article excluded owing to patient age or study quality was carefully examined and the impact of its exclusion assessed. One article was subsequently reintroduced in our review based on this assessment [11] .
CONCLUSION
CM has an important long-term impact on mortality and disability. Nevertheless, the quality of evidence is limited, and future CM research should focus not only on short-term medical outcomes but also on longer-term mortality, impairments, disability, and quality of life. In the meantime, fluconazole preemptive treatment, early diagnosis, and improved access to timely effective combined antifungal therapy should be implemented to prevent death and other long-term consequences of CM. In addition, early detection of impairments and access to rehabilitation services will improve quality of life in CM survivors.
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